Actively Recruiting
Assessment of Serum Catestatin Level in Acne Vulgaris Patients Before and After Treatment With Oral Isotretinoin
Led by Aswan University · Updated on 2025-07-08
60
Participants Needed
1
Research Sites
1 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults. Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.
CONDITIONS
Brief Title
Assessment of Serum Catestatin Level in Acne Vulgaris Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy persons of both sexes with moderate and severe acne.
You will not qualify if you...
- Pregnant and lactating women.
- Immunocompromised patients.
- Severe anemia.
- History of chronic liver disease.
- Hyperlipidemia
- Non-inflammatory acne conditions.
- History of neurologic disorders.
- History of neoplastic disorders.
- History of cardiac disease.
- History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks.
- Cases with known hypersensitivity reaction to isotretinoin.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aswan Unuversity Hospital
Aswān, Egypt
Actively Recruiting
Research Team
M
Mona Zakaria Mohamed, MSc
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here